Guggenheim Upgrades Sage Therapeutics (SAGE) to Buy
Tweet
Share
E-mail
Get Alerts SAGE Hot Sheet
Price: $32.30 --0%
Rating Summary:
14 Buy, 12 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 3 | Down: 10 | New: 7
Rating Summary:
14 Buy, 12 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 3 | Down: 10 | New: 7
Join SI Premium – FREE
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Guggenheim analyst Yatin Suneja upgraded Sage Therapeutics (NASDAQ: SAGE) from Neutral to Buy with a price target of $55.00.
For an analyst ratings summary and ratings history on Sage Therapeutics click here. For more ratings news on Sage Therapeutics click here.
Shares of Sage Therapeutics closed at $42.37 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Atlantic Equities Upgrades First Republic Bank (FRC) to Overweight
- UPDATE: JPMorgan Downgrades Huntington Bancshares (HBAN) to Neutral
- Northland Upgrades AMD Stock to Outperform as Macro Headwinds are Now Priced In
Create E-mail Alert Related Categories
UpgradesRelated Entities
GuggenheimSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
